Scalper1 News
Medical products giant Baxter International (BAX) beat Q3 earnings estimates and lifted its 2014 organic sales growth guidance Thursday, though it lowered its EPS outlook due to a divestiture. Its stock initially dropped but by early afternoon was up a fraction on the stock market today. Baxter’s sales rose 13% over the year-earlier quarter to $4.2 billion, in line with analysts’ consensus. Earnings climbed 9% to $1.35 a share, beating estimates Scalper1 News
Scalper1 News